Search

Your search keyword '"Hennig, Stefanie"' showing total 25 results
Start Over Author "Hennig, Stefanie" Publisher wiley
25 results on '"Hennig, Stefanie"'

3. Barriers to global pharmacometrics: educational challenges and opportunities across the globe

Author

Michelet, Robin, primary, Aulin, Linda B. S., additional, Borghardt, Jens M., additional, Costa, Teresa Dalla, additional, Denti, Paolo, additional, Ibarra, Manuel, additional, Ma, Guangda, additional, Meibohm, Bernd, additional, Pillai, Goonaseelan (Colin), additional, Schmidt, Stephan, additional, Hennig, Stefanie, additional, and Kloft, Charlotte, additional

Published
2023
Full Text
View/download PDF

7. Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications

Author

Tikiso, Tjokosela, primary, McIlleron, Helen, additional, Burger, David, additional, Gibb, Diana, additional, Rabie, Helena, additional, Lee, Janice, additional, Lallemant, Marc, additional, Cotton, Mark F., additional, Archary, Moherndran, additional, Hennig, Stefanie, additional, and Denti, Paolo, additional

Published
2021
Full Text
View/download PDF

24. Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management.

Author

Bista SR, Haywood A, Hardy J, Norris R, and Hennig S

Subjects
Administration, Cutaneous, Adult, Aged, Aged, 80 and over, Analgesics, Opioid administration & dosage, Analgesics, Opioid blood, Female, Humans, Male, Middle Aged, Tertiary Care Centers, Cancer Pain blood, Cancer Pain drug therapy, Fentanyl administration & dosage, Fentanyl blood, Pain Management methods, Transdermal Patch
Abstract

This study aimed to describe exposure after fentanyl transdermal patch administration in patients with advanced cancer to quantify variability around the exposure. Patients (n  =  56) with advanced cancer who received transdermal fentanyl (Durogesic®; median dose, 50 μg/h; range, 12-200 μg/h) provided venous blood samples (n  =  163) at various times (0.5-72 hours) during several patch application intervals. Plasma fentanyl concentration was determined (median, 0.9 μg/L; range, 0.04-9.7 μg/L) by high-performance liquid chromatography coupled to tandem mass spectrometry. Pharmacokinetic analysis was performed using nonlinear mixed-effects modeling with NONMEM. A 1-compartment distribution model with first-order absorption and elimination described fentanyl exposure after transdermal patch administration. Fentanyl apparent clearance (between-subject variability [BSV], %) was estimated at 122 L/h/70 kg and 38.5%, respectively. The absorption rate constant was 0.013 h(-1) . Between-occasion variability on apparent clearance was 22.0%, which was lower than BSV, suggesting predictable exposure within the same patient and justifying therapeutic drug monitoring. Except for weight-based dosing, no other patient characteristic could be identified to guide initial fentanyl dose selection in patients with advanced cancer., (© 2015, The American College of Clinical Pharmacology.)

Published
2016
Full Text
View/download PDF

25. Population pharmacokinetics of phenytoin in critically ill children.

Author

Hennig S, Norris R, Tu Q, van Breda K, Riney K, Foster K, Lister B, and Charles B

Subjects
Adolescent, Age Factors, Anticonvulsants administration & dosage, Anticonvulsants blood, Child, Child, Preschool, Critical Illness, Female, Hospitals, Pediatric, Humans, Infant, Infant, Newborn, Intensive Care Units, Pediatric, Linear Models, Male, Nonlinear Dynamics, Phenytoin administration & dosage, Phenytoin blood, Protein Binding, Anticonvulsants pharmacokinetics, Models, Biological, Phenytoin pharmacokinetics
Abstract

The objective was to study the population pharmacokinetics of bound and unbound phenytoin in critically ill children, including influences on the protein binding profile. A population pharmacokinetic approach was used to analyze paired protein-unbound and total phenytoin plasma concentrations (n = 146 each) from 32 critically ill children (0.08-17 years of age) who were admitted to a pediatric hospital, primarily intensive care unit. The pharmacokinetics of unbound and bound phenytoin and the influence of possible influential covariates were modeled and evaluated using visual predictive checks and bootstrapping. The pharmacokinetics of protein-unbound phenytoin was described satisfactorily by a 1-compartment model with first-order absorption in conjunction with a linear partition coefficient parameter to describe the binding of phenytoin to albumin. The partitioning coefficient describing protein binding and distribution to bound phenytoin was estimated to be 8.22. Nonlinear elimination of unbound phenytoin was not supported in this patient group. Weight, allometrically scaled for clearance and volume of distribution for the unbound and bound compartments, and albumin concentration significantly influenced the partition coefficient for protein binding of phenytoin. The population model can be applied to estimate the fraction of unbound phenytoin in critically ill children given an individual's albumin concentration., (© 2014, The American College of Clinical Pharmacology.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results